Overexpression of YAP/TAZ potentiates doxorubicin resistance in hepatocellular carcinoma (HCC) and conversely YAP/TAZ downregulation by RNA interference restores doxorubicin sensitivity [56,57] (Table 1). The gene discussed is YAP1; the disease is hepatocellular carcinoma.